Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pociredir phase 1 safety, tolerability, pharmacokinetics, and pharmacodynamics study in adults with sickle cell disease
PACTR202503747135772Phase 1Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pociredir in sickle cell disease (SCD), sponsored by Fulcrum Therapeutics. Started Apr 2025; status: completed.
02
Drugs
pociredir
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202503747135772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503747135772.